MenAfriVac

MenAfriVac

MenAfriVac is a vaccine developed for use in sub-Saharan Africa that protects people 1 to 29 years of age against meningococcal bacterium Neisseria meningitidis group A. MenAfriVac costs under US$.50 per dose and reduces carriage of the bacteria from one person to another.[1][2][3] The Meningitis Vaccine Project, a partnership between the Program for Appropriate Technology in Health (PATH) and the World Health Organization, worked with a consortium of international partners to develop the vaccine.[4]

Contents

History

The largest meningitis epidemic in African history swept across sub-Saharan Africa from 1996 to 1997, numbering 250,000 new cases of the disease and taking 25,000 lives. Three years later, the World Health Organization held a technical consultation in Cairo, Egypt with African ministers of health and global health leaders to discuss meningitis and the development of a new vaccine. At that meeting, representatives from eight African countries issued a statement saying that the development of a meningococcal vaccine to prevent epidemics was a high priority for them, and concluded that a conjugate meningococcal vaccine would have the potential to prevent future epidemics. They estimated that the new vaccine could become available in three to seven years for US$ 0.40 to $ 1 a dose, providing protection for at least ten years.[5]

A year later, in 2001, the Bill & Melinda Gates Foundation provided a ten-year, $70 million grant to establish the Meningitis Vaccine Project, a partnership between PATH and the World Health Organization. The foundation charged the new project with development, testing, licensure, and mass introduction of a meningococcal conjugate vaccine.[6] In 2002, the newly-funded collaboration supported reinforced meningitis surveillance activities in 12 countries in Africa: Benin, Burkina Faso, Cameroon, Central African Republic, Chad, Côte d’Ivoire, Ethiopia, Ghana, Mali, Niger, Nigeria, and Togo. Data from the surveillance indicated an increased risk of outbreaks in the future and the continued need for a conjugate A meningitis vaccine.[7] MenAfriVac is available for widespread use in African meningitis belt countries.[4]

Manufacture

The Meningitis Vaccine Project partnered with SynCo Bio Partners, a Dutch biotech company, and the US government’s Center for Biologics Evaluation and Research to develop MenAfriVac, and the Serum Institute of India to manufacture it.

MenAfriVac is a freeze-dried vaccine of a polysaccharide from a type of Neisseria meningitidis called group A. The polysaccharide has been purified by affinity chromatography and bound to a carrier protein called tetanus toxoid. The TT is prepared by extraction by ammonium sulfate precipitation and the toxin is inactivated with formalin the toxin from cultures of Clostridium tetani grown in a modified Mueller-Hinton agar.[8]

References

  1. ^ Butler, Declan. "Vaccine offers meningitis hope". November 9, 2010. Nature News. http://www.nature.com/news/2010/101109/full/468143a.html?s=news_rss. Retrieved 24 November 2010. 
  2. ^ Bowdler, Neil (22 November 2010). "New jab for millions across African ‘meningitis belt". November 22, 2010 (BBC News). http://www.bbc.co.uk/news/health-11813238. Retrieved November 23, 2010. 
  3. ^ "New Meningitis Vaccine a ‘Revolution". October 14, 2010. allAfrica.com. http://allafrica.com/stories/201010140944.html. Retrieved November 24, 2010. 
  4. ^ a b Anderson, Tatum (14 October 2010). "Africa hails new meningitis vaccine". 14 October 2010 (BBC News). http://www.bbc.co.uk/news/business-11534311. Retrieved 24 November 2010. 
  5. ^ "Improved meningitis vaccine for Africa could signal eventual end to deadly scourge". 8 June 2007. World Health Organization. http://www.who.int/mediacentre/news/releases/2007/pr28/en/. Retrieved 24 November 2010. 
  6. ^ "The Bill & Melinda Gates Foundation Announces Grant for the Elimination of Epidemic Meningitis in Sub-Saharan Africa". May 30, 2001. Bill & Melinda Gates Foundation. http://www.gatesfoundation.org/press-releases/Pages/path-and-who-receive-grant-010530.aspx. Retrieved 24 November 2010. 
  7. ^ "WHO weekly epidemiology record". September 16. 2005. World Health Organization. http://www.who.int/wer/2005/wer8037.pdf. Retrieved 24 November 2010. 
  8. ^ "MenAfriVac Meningococcal A Conjugate Vaccine". seruminstitute.com. Serum Institute of India. 2011. http://www.seruminstitute.com/content/products/product_menafrivac.htm. Retrieved 17 June 2011. 

External link

product page

v · d · e Program for Appropriate Technology in Health (PATH)
Key people
Projects
Products
MenAfriVac · Uniject · SILCS diaphragm · Ultra Rice
Retrieved from "http://en.wikipedia.org/wiki/MenAfriVac"

Wikimedia Foundation. 2010.

Игры ⚽ Нужна курсовая?

Look at other dictionaries:

  • Meningitis Vaccine Project — The Meningitis Vaccine Project is an effort to eliminate the meningitis epidemic in Sub Saharan Africa by developing a new meningococcal vaccine. The meningitis problem in that area is caused by a strain of meningitis called meningitis A , which… …   Wikipedia

  • Meningitis — Classification and external resources Meninges of the central nervous system: dura mater, arachnoid, and pia mater. ICD 10 G …   Wikipedia

  • Combined injectable contraceptive — Background Birth control type Hormonal First use about 1980 Failure rates (first year) Perfect use 0 0.2 …   Wikipedia

  • Christopher Elias — Dr. Christopher J. Elias is the president and CEO of the Program for Appropriate Technology in Health, also known as PATH, a nonprofit organization that improves global health by ensuring that innovations in science and technology are available… …   Wikipedia

  • Meningococcal vaccine — Vaccine description Target disease Neisseria meningitidis Type  ? Clinical data AHFS/Drugs.com …   Wikipedia

Share the article and excerpts

Direct link
… Do a right-click on the link above
and select “Copy Link”